FNYS
FLNA

First New York Securities’s Filana Therapeutics FLNA Stock Holding History

First New York Securities’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-100
Closed -$3K – 460
2013
Q4 		$3K Buy
+100
New +$2.65K ﹤0.01% 260

Other funds holding FLNA

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
MSP
Madison Street Partners Denver, Colorado $3.05M AUM 5.94% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
SC
Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

First New York Securities's FLNA Position: Q1 2014 in Review

First New York Securities sold out of Filana Therapeutics (FLNA) in Q1 2014, closing a stake of 100 shares — an estimated $3K sold.

First New York Securities first reported a position in FLNA in Q4 2013 and held it in 1 quarter. The position peaked at $3K in Q4 2013. 75 funds tracked by Wall St. Rank hold FLNA as of Q1 2014.

  • First New York Securities reported no remaining Filana Therapeutics position as of Q1 2014 after selling out during the quarter.
  • First New York Securities sold 100 Filana Therapeutics shares in Q1 2014, an estimated $3K.
  • First New York Securities first reported a position in Filana Therapeutics in Q4 2013 and held it in 1 quarter.
  • First New York Securities's Filana Therapeutics position peaked at $3K in Q4 2013.
  • 75 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2014.

Based on First New York Securities's 13F filing for Q1 2014, filed 15 May 2014.